Pharmacokinetics and Safety of an Intravitreal Humanized Anti-VEGF-A Monoclonal Antibody (PRO-169), a Biosimilar Candidate to Bevacizumab.
Patricia Del Carmen Muñoz-VillegasAlejandra Sanchez-RiosMayra G Quinonez-AlvaradoOscar Olvera-MontañoJuan D Quintana-HauLeopoldo Baiza-DuranPublished in: Journal of experimental pharmacology (2021)
PRO-169 can be efficiently diffused and distributed in ocular compartments, showing vitreous pharmacokinetics analogous to BEV. The safety experiment did not find evidence of clinical alterations from a repeated injection of PRO-169. These results provide scientific justification supporting that PRO-169 should be evaluated in future clinical trials to confirm its safety and efficacy.